Get notified of page updates

Comparing an Investigational Targeted Drug AZD5335 to Standard Treatments in People With Platinum‑Resistant Ovarian Cancer (TREVI‑OC‑01)

Treatment

Phase 3 treatment study for platinum-resistant ovarian cancer

Clinicaltrials.gov identifier:
NCT07218809

Study Contact Information:

AstraZeneca Clinical Study Information Center
📞 1‑877‑240‑9479
📧 [email protected]

PRINTER FRIENDLY PAGE
Overview
Who Can Join
Details
Contact
Locations
Glossary on
off

About the Study

This study is testing whether a new called AZD5335 works better than currently used treatments for people with platinum‑resistant ovarian, , or primary peritoneal cancer. The study is looking at how long people live without their cancer getting worse while taking AZD5335 compared with standard treatments. 

AZD5335 is a type of  known as an antibody-drug conjugate (ACD). ACDs are made up of an antibody attached to chemotherapy. The antibody binds to the cancer cell and delivers the chemotherapy directly into the cell. 

This study is open to people whose cancer returned or got worse after receiving a . 

This Study is Open To:

People may be eligible if they have all of the following: 

  • Are 18 years or older.
  • High‑grade ovarian cancer, cancer, or primary peritoneal cancer.
  • Cancer that is platinum‑resistant (it came back within 6 months after platinum chemotherapy).
  • Received 1 to 3 prior lines of treatment
  • Are well enough to receive single‑agent treatment.

  • People with a known mutation must have already received a , if appropriate, unless they could not tolerate it.

This Study is NOT Open To:

People cannot participate if they have any of the following: 

  • The cancer is primary platinum refractory, which means it didn't respond or got worse on platinum chemotherapy. 
  • Active or chronic corneal (eye surface) problems.
  • Have a history of serious lung inflammation (ILD or pneumonitis) or significant lung disease.

What the Study Involves

Before joining, each participant’s tumor will be tested for known as folate receptor alpha (FRα). Based on the results, participants will be placed into one of two groups. 

FRα‑High Group

People whose tumor is FRα-high will be randomly assigned to one of two groups. One group will receive the investigational drug AZD5335 and the other group will receive an FDA-approved drug called Elahere (mirvetuximab soravtansine). Both drugs are a type of  known as an antibody-drug conjugate (ACD). ACDs are made up of an antibody attached to chemotherapy. The antibody binds to the cancer cell and delivers the chemotherapy directly into the cell. 

  • AZD5335 group: People in this group will receive the investigational drug AZD5335 by intravenous (IV) injection every three weeks. 
  • Standard of care group: People in this group will receive the drug Elahere (mirvetuximab soravtansine) by intravenous (IV) injection every three weeks.

FRα‑Low Group

People whose tumor is FRα-high will be randomly assigned to one of two groups. One group will receive the investigational drug AZD5335 and the other group will receive standard chemotherapy. 

  • AZD5335 group: People in this group will receive the investigational drug AZD5335 by intravenous (IV) injection every three weeks. 
  • Standard chemotherapy group: People in this group will receive their doctor's choice of chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan). The frequency of treatment will depend on which chemotherapy is selected. 

Treatment continues until one of the following happens:

  • The cancer gets worse
  • Side effects become unacceptable or unsafe
  • The participant or doctor decides to stop treatment for another medical reason
  • The participant chooses to stop the study treatment

All participants will be followed for several years, even after they stop the study treatment.

Study Contact Information:

AstraZeneca Clinical Study Information Center
📞 1‑877‑240‑9479
📧 [email protected]

Locations:

Alabama

City: Birmingham RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

District of Columbia

City: Washington D.C. RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Florida

City: Gainesville RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

City: Jupiter RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

City: Miami RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Illinois

City: Peoria RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

City: Urbana RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Indiana

City: Fort Wayne RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

City: Indianapolis RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Kentucky

City: Louisville RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Massachusetts

City: Burlington RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Maryland

City: Towson RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Minnesota

City: Minneapolis RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Missouri

City: Springfield RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Montana

City: Billings RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

North Carolina

City: Chapel Hill RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Nebraska

City: Omaha RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Nevada

City: Las Vegas RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Ohio

City: Blue Ash RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

City: Dayton RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Oregon

City: Portland RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Tennessee

City: Germantown RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Texas

City: San Antonio RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

City: Tyler RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Virginia

City: Fairfax RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

City: Roanoke RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Washington

City: Seattle RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Other Countries

Country: Australia
City: Adelaide RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Australia
City: Auchenflower RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Australia
City: Campbelltown RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Australia
City: Garran RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Australia
City: Gosford RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Australia
City: Heidelberg RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Australia
City: Kogarah RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Australia
City: Melbourne RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Australia
City: Richmond RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Australia
City: St Leonards RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Australia
City: Waratah RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Belgium
City: Ghent RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Belgium
City: Leuven RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Belgium
City: Libramont-Chevigny RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Belgium
City: Namur RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: China
City: Wuhan RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: France
City: Avignon RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: France
City: Paris RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: France
City: Pau RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: France
City: Pierre-Bénite RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: France
City: Saint-Herblain RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: France
City: Saint-Priest-en-Jarez RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: France
City: Tours RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Israel
City: Beersheba RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Israel
City: Hadera RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Israel
City: Haifa RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Israel
City: Haifa RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Israel
City: Holon RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Israel
City: Jerusalem RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Israel
City: Jerusalem RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Israel
City: Kfar Saba RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Israel
City: Nahariya RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Israel
City: Tel Aviv RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Hidaka-shi RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Kobe RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Kurume-shi RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Kōtoku RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Niigata RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Osaka RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Sagamihara-shi RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Sapporo RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Sendai RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Shinjuku-ku RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Shinjuku-ku RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Shiwa-gun RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Toon-Shi RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Tsu RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Busan RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Daegu RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Goyang-si RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Seongnam-si RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Seoul RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Seoul RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Seoul RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Seoul RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Seoul RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Seoul RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Suwon RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Yangsan RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Taiwan
City: Taipei RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Thailand
City: Bangkok RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: United Kingdom
City: Barrow in Furness RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: United Kingdom
City: Edinburgh RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: United Kingdom
City: Greater London RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: United Kingdom
City: London RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: United Kingdom
City: Nottingham RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: United Kingdom
City: Sutton RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: United Kingdom
City: Swansea RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Treatment

Phase 3 treatment study for platinum-resistant ovarian cancer

Clinicaltrials.gov identifier:
NCT07218809

Study Contact Information:

AstraZeneca Clinical Study Information Center
📞 1‑877‑240‑9479
📧 [email protected]

PRINTER FRIENDLY PAGE